NCT04176718: Phase 2 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

NCT04176718: Phase 2 - Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Dara-KPd

This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma.

Sponsor

Andrew Yee, MD

Collaborators

Amgen

Janssen Research & Development, LLC

---

ClinicalTrials.gov Identifier: NCT04176718

Official Title: A Phase II Study of Daratumumab With Weekly Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

First Posted : November 25, 2019

Click here for ClinicalTrials.gov

---

Daratumumab : National Cancer Institute

Daratumumab : MedlinePlus Drug Information

Daratumumab and Hyaluronidase-fihj Injection: National Cancer Institute

Daratumumab and Hyaluronidase-fihj Injection: MedlinePlus Drug Information

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information

Pomalidomide: National Cancer Institute

Pomalidomide : MedlinePlus Drug Information

Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information

---

Drug: Daratumumab

Drug: Carfilzomib

Drug: Pomalidomide

Drug: Dexamethasone

---

Location

United States, Massachusetts